Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
02/25/15Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. ET at the Boston Marriott Copley Place Hotel in Boston. A live audio webcast of the presentation will be available on the Investors sect... 
Printer Friendly Version
02/18/15Alnylam to Webcast Presentation at 2015 RBC Capital Markets’ Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2015 RBC Capital Markets’ Global Healthcare Conference on Wednesday, February 25, 2015 at 9:30 a.m. ET at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors secti... 
Printer Friendly Version
02/12/15Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress
– Introduced Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs,” and Launched “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics – – Presented Positive Data from Multiple Clinical Programs, Including Initial Evidence of Potential Disease Modifying Effects with Patisiran and ALN-AT3 – – Advanced Revusiran into ENDEAVOUR Phase 3 Trial and Added Three New Pro... 
Printer Friendly Version
02/05/15Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2014 on Thursday, February 12, 2015, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year-end 2014 results, and discuss expectations fo... 
Printer Friendly Version
02/03/15Alnylam to Webcast Presentation at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 11:00 a.m. ET at the Waldorf Astoria in New York City. In addition, Alnylam management will present a company overview at the 2015 Leerink Global Healthca... 
Printer Friendly Version
02/02/15Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
Company Expects to Present Initial Clinical Results in Mid-2015 with Additional Data in Late 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-m... 
Printer Friendly Version
01/20/15Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 20, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $450 million. All of the shares in the offering are to be sold by Alnylam. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-runn... 
Printer Friendly Version
01/20/15Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 20, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of $95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015, subject to the satisfaction of customary ... 
Printer Friendly Version
01/11/15Alnylam Reports Initial Evidence for Potential Correction of the Hemophilia Phenotype in Phase 1 Study of ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia
– In New Data from Hemophilia Subjects, ALN-AT3 Achieves Antithrombin Knockdown of up to 70%, Increases Thrombin Generation by up to 334%, and Markedly Improves Whole Blood Clotting – – ALN-AT3 Administration Remains Generally Well Tolerated – – Company to Webcast Conference Call at 8:30 a.m. ET (5:30 a.m. PT) Tomorrow, January 12, to Discuss Data – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2015-- Alnylam Pharm... 
Printer Friendly Version
01/09/15Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
New Agreement Includes Cross-License on Four Disease Targets, Providing Each Company Exclusive RNA Therapeutic License Rights for Two Programs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in ... 
Printer Friendly Version
01/08/15Alnylam Launches “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics
– By End of 2020, Company Expects to Achieve Profile with 3 Marketed Products, 10 RNAi Therapeutic Clinical Programs - Including 4 in Late Stages - Across 3 Strategic Therapeutic Areas (STArs) – – Provides Goals and Guidance for 2015, Exceeding its “Alnylam 5x15” Guidance Established in 2011 and Further Updated in 2014 – – Increases Guidance to End 2014 with Approximately $880 Million in Cash – CAMBRIDGE, Mass.--(BUSINESS WIRE)... 
Printer Friendly Version
01/05/15Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias
Company Expects to Initiate Phase 1 Study in Mid-2015 with Initial Clinical Results in Early 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Swedish Medical Products Agency (MPA) to initiate a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigation... 
Printer Friendly Version
01/05/15Alnylam to Webcast Presentation at 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2015-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 10:00 a.m. PT (1:00 p.m. ET) at the Westin St. Francis Hotel in San Francisco, Calif. This presentation will include a review of the company’s goals and guidance. ... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.